Abstract
Hyperuricemia associated with cisplatin therapy is considered to be a consequence of cisplatin-induced nephrotoxic reactions. We correlated changes in serum uric acid levels in patients with malignant neoplasms with tissue levels of platinum and the total dose of cisplatin. In 15 patients, the serum uric acid level increased from 6.1 +/- 1.0 mg/dL to 8.3 +/- 1.3 mg/dL during the time they were receiving cisplatin therapy. The change in uric acid level from baseline to peak correlated with both the total dose of cisplatin and the liver platinum concentration. There was no correlation with platinum concentration in the renal cortex and medulla.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
